Poor response to hepatitis A vaccination in hematopoietic stem cell transplant recipients.

Autor: Adati EM; HSCT Program, Amaral Carvalho Foundation, Jahu, Brazil., da Silva PM; Núcleo de Apoio ao Pesquisador, Hospital do Amor, Barretos, Brazil., Sumita LM; Virology Laboratory (LIM 52-HCFMUSP), Institute of Tropical Medicine-University of São Paulo Medical School, São Paulo, SP, Brazil., Rodrigues MO; Universidade Paulista, Instituto de Ciências da Saúde, Bauru, Brazil., Zanetti LP; HSCT Program, Amaral Carvalho Foundation, Jahu, Brazil., Dos Santos ACF; HSCT Program, Amaral Carvalho Foundation, Jahu, Brazil., de Souza MP; HSCT Program, Amaral Carvalho Foundation, Jahu, Brazil., Colturato VR; HSCT Program, Amaral Carvalho Foundation, Jahu, Brazil., Machado CM; HSCT Program, Amaral Carvalho Foundation, Jahu, Brazil.; Virology Laboratory (LIM 52-HCFMUSP), Institute of Tropical Medicine-University of São Paulo Medical School, São Paulo, SP, Brazil.
Jazyk: angličtina
Zdroj: Transplant infectious disease : an official journal of the Transplantation Society [Transpl Infect Dis] 2020 Jun; Vol. 22 (3), pp. e13258. Date of Electronic Publication: 2020 Feb 24.
DOI: 10.1111/tid.13258
Abstrakt: Background: Hepatitis A virus (HAV) infection is highly prevalent in developing countries. In countries experiencing a shift from intermediate/high endemicity to low endemicity, the World Health Organization recommends the incorporation of HAV vaccine into the national vaccination calendar for children aged ≥1 year. Since HAV antibodies wane over time, most HSCT revaccination guidelines advise vaccination as optional, following the country recommendation. However, no study has evaluated the serological response to HAV vaccine in allogeneic HSCT recipients.
Methods: We conducted a prospective study in 46 HSCT recipients who received two doses of inactivated HAV vaccine. Blood samples were taken before vaccination to determine HAV prevalence rates, and before and 4-6 weeks after the second dose. Specific anti-HAV antibodies were detected by a competitive commercial enzyme immune assay.
Results: Patients received the first dose of vaccine at a median of 332.5 (120-4134) days after HSCT. Median absolute lymphocyte count at vaccination was 1947 (696-12 500)/mm 3 . The seroprevalence rate was 93.5% at inclusion. Although safe and well tolerated, the serological response to HAV vaccine in susceptible patients was poor (33%), and no boost effect was observed in seropositive patients.
Conclusions: In areas with intermediate/high seroprevalence of HAV, serology should be recommended prior to referral to vaccination. The mechanisms of antibody interference and how to overcome T-cell function deficiency need to be better understood in transplant populations receiving HAV vaccine. Alternative schedules of HAV vaccination should be evaluated in prospective trials.
(© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje